Nutex Health (NUTX) Stock: Buy, Sell, or Hold?
NUTX - Nutex Health Inc. Common Stock
$206.09
8.48 (4.29%)
▲
5d:
+2.63%
30d:
+2.1%
90d:
+41.28%
BUY
MODERATE Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 05, 2026
12d
Get Alerted When NUTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NUTX shows positive signals but monitor for confirmation. Market pricing in 1.6% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: NUTX shows positive signals but monitor for confirmation. Market pricing in 1.6% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$385.37
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$239.28
13.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NUTX is currently trading at $206.09, which is considered fair relative to its 30-day fair value range of $199.16 to $216.63. The stock's valuation (Forward PE: 7.4) is in line with its historical norms (7.1). At these levels, the market is pricing in 1.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, NUTX is in a strong uptrend. The price is approaching resistance at $212.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.3% recently.
Market Sentiment: NUTX scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $288.20 (+39.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NUTX is in a strong uptrend. The price is approaching resistance at $212.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.3% recently.
Market Sentiment: NUTX scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $288.20 (+39.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$199.16 -
$216.63
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.0%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (65/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.3%)
- BULLISH: Trading 39.8% below Wall St target ($288.20)
- NEUTRAL: Market pricing in 1.6% annual earnings growth - fairly valued
- BULLISH: Bottoming setup score 65/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$199.16 -
$216.63
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$182.90
Resistance Level
$212.00
Current Trend
Strong Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.39
Wall Street Target
$288.20
(+39.8%)
Revenue Growth (YoY)
-13.6%
Earnings Growth (YoY)
95.9%
Profit Margin
21.2%
Valuation Premium vs History
+1.6% premium
PE vs Historical
7.4 vs 7.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.6%
(market-implied from PE analysis)
1-Year Target
$209.39
(+2%)
2-Year Target
$212.74
(+3%)
3-Year Target
$216.14
(+5%)
3-Yr Target (if PE normalizes)
(PE: 7→7)
PE COMPRESSION
$207.54
(+1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 28.1%)
$558.21
(+171%)
Base:
(SPY PE: 7.4, Growth: 28.1%)
$207.83
(+1%)
Bear:
(PE: 6.3, Growth: 28.1%)
$176.66
(-14%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (8x PE), but valuation improves significantly next year (7x PE) as earnings recover.
Trailing PE: 7.83 | Current EPS (TTM): $25.24
Bull Case
$240.04
(+17%)
Analyst growth 10.4%, PE expands to 8.6
Base Case
$218.22
(+6%)
Market implied 10.4%, PE stable at 7.8
Bear Case
$134.37
(-35%)
Severe decline -20.0%, PE contracts to 6.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 22, 2026 7:27 PM ET
Data refreshes hourly during market hours. Next update: 8:27 PM
Data refreshes hourly during market hours. Next update: 8:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NUTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Care Facilities Stocks
Top-rated stocks in Medical Care Facilities by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
THC
Tenet Healthcare Corpora… |
STRONG BUY
23 analysts |
$286 | 54 HOLD |
|
HCA
HCA Healthcare, Inc. |
BUY
26 analysts |
$461 | 50 HOLD |
|
CMPS
Compass Pathways Plc |
STRONG BUY
16 analysts |
$24 | 61 BUY |
|
EHC
Encompass Health Corp |
STRONG BUY
13 analysts |
$148 | 60 HOLD |
|
GRDN
Guardian Pharmacy Servic… |
STRONG BUY
7 analysts |
$50 | 60 BUY |
